Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/CAMK2B_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/CAMK2B_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CAMK2B_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/CAMK2B_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0022604 | Colorectum | AD | regulation of cell morphogenesis | 109/3918 | 309/18723 | 3.08e-09 | 2.07e-07 | 109 |
GO:0046777 | Colorectum | AD | protein autophosphorylation | 74/3918 | 227/18723 | 2.48e-05 | 4.76e-04 | 74 |
GO:0010975 | Colorectum | AD | regulation of neuron projection development | 129/3918 | 445/18723 | 2.88e-05 | 5.37e-04 | 129 |
GO:0106027 | Colorectum | AD | neuron projection organization | 36/3918 | 93/18723 | 6.58e-05 | 1.07e-03 | 36 |
GO:0031346 | Colorectum | AD | positive regulation of cell projection organization | 104/3918 | 353/18723 | 8.26e-05 | 1.30e-03 | 104 |
GO:0010769 | Colorectum | AD | regulation of cell morphogenesis involved in differentiation | 35/3918 | 96/18723 | 3.26e-04 | 3.85e-03 | 35 |
GO:0010770 | Colorectum | AD | positive regulation of cell morphogenesis involved in differentiation | 30/3918 | 79/18723 | 3.81e-04 | 4.38e-03 | 30 |
GO:0010720 | Colorectum | AD | positive regulation of cell development | 87/3918 | 298/18723 | 4.17e-04 | 4.71e-03 | 87 |
GO:0097061 | Colorectum | AD | dendritic spine organization | 31/3918 | 84/18723 | 5.48e-04 | 5.83e-03 | 31 |
GO:0090257 | Colorectum | AD | regulation of muscle system process | 73/3918 | 252/18723 | 1.46e-03 | 1.24e-02 | 73 |
GO:0050767 | Colorectum | AD | regulation of neurogenesis | 99/3918 | 364/18723 | 2.35e-03 | 1.82e-02 | 99 |
GO:0099173 | Colorectum | AD | postsynapse organization | 51/3918 | 168/18723 | 2.47e-03 | 1.90e-02 | 51 |
GO:0016358 | Colorectum | AD | dendrite development | 69/3918 | 243/18723 | 3.32e-03 | 2.42e-02 | 69 |
GO:0050808 | Colorectum | AD | synapse organization | 112/3918 | 426/18723 | 4.25e-03 | 2.92e-02 | 112 |
GO:0050807 | Colorectum | AD | regulation of synapse organization | 60/3918 | 211/18723 | 5.67e-03 | 3.64e-02 | 60 |
GO:0043502 | Colorectum | AD | regulation of muscle adaptation | 31/3918 | 98/18723 | 8.45e-03 | 4.94e-02 | 31 |
GO:00226041 | Colorectum | SER | regulation of cell morphogenesis | 89/2897 | 309/18723 | 1.51e-09 | 1.52e-07 | 89 |
GO:01060271 | Colorectum | SER | neuron projection organization | 33/2897 | 93/18723 | 1.64e-06 | 7.23e-05 | 33 |
GO:00970611 | Colorectum | SER | dendritic spine organization | 29/2897 | 84/18723 | 1.27e-05 | 4.01e-04 | 29 |
GO:00467771 | Colorectum | SER | protein autophosphorylation | 60/2897 | 227/18723 | 1.36e-05 | 4.25e-04 | 60 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CAMK2B | SNV | Missense_Mutation | novel | c.152N>T | p.Ser51Leu | p.S51L | Q13554 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.997) | TCGA-AX-A2HG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CAMK2B | SNV | Missense_Mutation | | c.778C>T | p.Arg260Cys | p.R260C | Q13554 | protein_coding | deleterious_low_confidence(0) | probably_damaging(1) | TCGA-B5-A11H-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Hormone Therapy | megace | SD |
CAMK2B | SNV | Missense_Mutation | novel | c.1173N>G | p.Ile391Met | p.I391M | Q13554 | protein_coding | tolerated_low_confidence(0.06) | possibly_damaging(0.77) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
CAMK2B | SNV | Missense_Mutation | rs780774430 | c.224N>A | p.Arg75His | p.R75H | Q13554 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.994) | TCGA-BG-A3EW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
CAMK2B | SNV | Missense_Mutation | | c.1957N>A | p.Val653Met | p.V653M | Q13554 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.984) | TCGA-D1-A169-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | PD |
CAMK2B | SNV | Missense_Mutation | novel | c.607N>G | p.Ile203Val | p.I203V | Q13554 | protein_coding | deleterious_low_confidence(0.03) | benign(0.199) | TCGA-D1-A175-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
CAMK2B | SNV | Missense_Mutation | novel | c.1287G>T | p.Glu429Asp | p.E429D | Q13554 | protein_coding | tolerated_low_confidence(0.34) | benign(0.074) | TCGA-DF-A2KN-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
CAMK2B | SNV | Missense_Mutation | novel | c.965N>A | p.Ala322Asp | p.A322D | Q13554 | protein_coding | deleterious_low_confidence(0.03) | possibly_damaging(0.63) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
CAMK2B | SNV | Missense_Mutation | novel | c.1801N>G | p.Thr601Ala | p.T601A | Q13554 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.94) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
CAMK2B | SNV | Missense_Mutation | novel | c.1820N>C | p.Val607Ala | p.V607A | Q13554 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.997) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
816 | CAMK2B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | TRIFLUOPERAZINE | TRIFLUOPERAZINE | 15845548 |
816 | CAMK2B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | TAE-684 | TAE-684 | |
816 | CAMK2B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | GSK-269962A | GSK-269962A | |
816 | CAMK2B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | HYDROGEN PEROXIDE | | 15304367 |
816 | CAMK2B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | LINIFANIB | LINIFANIB | |
816 | CAMK2B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | inhibitor | 135652717 | STAUROSPORINE | |
816 | CAMK2B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | SOTRASTAURIN | SOTRASTAURIN | |
816 | CAMK2B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | IONOMYCIN | IONOMYCIN | 12193581,15845548 |
816 | CAMK2B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | VASOPRESSIN | VASOPRESSIN | 15845548 |
816 | CAMK2B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | CEDIRANIB | CEDIRANIB | |